Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Paul Linh Nguyen, M.D.

Co-Author

This page shows the publications co-authored by Paul Nguyen and Jason Efstathiou.
Connection Strength

2.577
  1. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3.
    View in: PubMed
    Score: 0.176
  2. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12.
    View in: PubMed
    Score: 0.168
  3. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9.
    View in: PubMed
    Score: 0.164
  4. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83.
    View in: PubMed
    Score: 0.163
  5. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85.
    View in: PubMed
    Score: 0.162
  6. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8.
    View in: PubMed
    Score: 0.155
  7. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72.
    View in: PubMed
    Score: 0.154
  8. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21.
    View in: PubMed
    Score: 0.147
  9. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12.
    View in: PubMed
    Score: 0.145
  10. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.143
  11. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.136
  12. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.131
  13. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
    View in: PubMed
    Score: 0.127
  14. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1081-5.
    View in: PubMed
    Score: 0.111
  15. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
    View in: PubMed
    Score: 0.110
  16. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
    View in: PubMed
    Score: 0.060
  17. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):174-185.
    View in: PubMed
    Score: 0.057
  18. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031.
    View in: PubMed
    Score: 0.056
  19. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743.
    View in: PubMed
    Score: 0.056
  20. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948.
    View in: PubMed
    Score: 0.053
  21. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147.
    View in: PubMed
    Score: 0.045
  22. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Jul 01; 80(3):928-37.
    View in: PubMed
    Score: 0.029
  23. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.